Neural networks have been extensively used in the proteomics field and their role on improving identifications is rapidly becoming more relevant. DeepiRT is a neural network designed to predict Indexed Retention Time (iRT) (Escher, 2012) for a given precursor based on its modified sequence.

Our collaborator, GreyWolf Therapeutics, has uncovered the effect of aminopeptidase ERAP2 inhibition for generating the de novo antitumor T-cell responses, thereby overcoming the resistance mechanism for current immune-oncology therapy.

Learn more about leveraging our TrueDiscovery® immunopeptidomics CRO services to overcome the challenges in immune-oncology.

Disclaimer: The contact information provided for poster download will also be shared with GreyWolf Therapeutics

This poster delves into the ULTRA-DEEP EXPLORATION OF HUMAN TISSUE PROTEOMES, where 20025 protein groups were identified across all 22 tissue samples (19 healthy and 3 cancer). The poster concludes that the qualitative human tissue digital proteome serves as a rich resource that can be mined for various applications such as basal protein expression, different proteoforms, PTMs etc.

Presenter: Amaury Lachaud

Date: Wednesday, Sep 20, 2023, 11:45 AM – 1:00 PM
Session: PP05

Presenter: Roland Bruderer
Date: November 7

Alterations in biofluid proteomes are powerful molecular biosignatures for the screening and diagnosis of bladder and kidney-related diseases. At HUPO 2022, Roland Bruderer presented a poster on how we identified actionable biomarkers for bladder cancer and chronic kidney disease in urine with our TrueDiscovery™ platform for deep unbiased mass-spectrometry-based proteomics.

From the total of 12,617 proteins identified in the urine samples, we revealed changes in proteins involved in programmed cell death, telomerase organization, keratinocyte, and epidermal cell differentiation, as well as inflammation markers and previously described markers such as urokinase plasminogen activator surface receptor (UPAR). Of the altered proteins analyzed, 23 significantly differentiated the pathophysiological conditions. Download the poster to discover more.

E-Poster 1374/5 presented at AACR 2022

Presenter: Marco Tognetti
Session: PO.IM01.05 – Tumor Antigens, Antigen Presentation, and Tumor Immunity
Date: April 11

E-poster presented at AACR 2021

Presenter: Yuehan Feng
A collaboration with:  Cedilla Therapeutics

E-poster session April 10, 8:30 AM – 11:59 PM US EDT: PO.CH01.06 – Lead Identification and Optimization

Abstract

Poster 1267/14 presented at AACR 2022

Presenter: Jakob Vowinckel
Session: PO.CL11.07 Biomarkers Predictive of Therapeutic Benefit 2
Date: April 11

Mass spectrometry (MS)-based proteomics allows the comprehensive identification and quantification of proteins in various biological specimen such as cell lines, body fluids or tissues. The study of these complex samples for applications like biomarker discovery requires large sample cohorts with low technical variability to overcome inter-individual differences and achieve sufficient statistical power.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More